Last reviewed · How we verify

Vonoprazan and Amoxicillin — Competitive Intelligence Brief

Vonoprazan and Amoxicillin (Vonoprazan and Amoxicillin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin). Area: Gastroenterology / Infectious Disease.

marketed Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vonoprazan and Amoxicillin (Vonoprazan and Amoxicillin) — Kaohsiung Medical University. Vonoprazan inhibits gastric acid secretion by blocking the proton pump, while amoxicillin is a beta-lactam antibiotic that kills Helicobacter pylori bacteria by disrupting cell wall synthesis.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vonoprazan and Amoxicillin TARGET Vonoprazan and Amoxicillin Kaohsiung Medical University marketed Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Vonoprazan+amoxicillin+clarithromycin 7 days Vonoprazan+amoxicillin+clarithromycin 7 days Xijing Hospital of Digestive Diseases marketed Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin) H+/K+-ATPase (vonoprazan); bacterial cell wall and ribosome (amoxicillin and clarithromycin)
Vonoprazan+amoxicillin+clarithromycin 14 days Vonoprazan+amoxicillin+clarithromycin 14 days Xijing Hospital of Digestive Diseases marketed Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin) H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)
Vonoprazan and Amoxicillin for 14 days Vonoprazan and Amoxicillin for 14 days The First Affiliated Hospital with Nanjing Medical University marketed Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) H+/K+-ATPase (vonoprazan); bacterial penicillin-binding proteins (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) class)

  1. Kaohsiung Medical University · 1 drug in this class
  2. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vonoprazan and Amoxicillin — Competitive Intelligence Brief. https://druglandscape.com/ci/vonoprazan-and-amoxicillin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: